Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Comparison | Eligibility | NCT01313039 | NCT01031446 | Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the father from the study interventions. | Contradiction | [
9
] | [
19
] | {'Clinical Trial ID': 'NCT01313039', 'Intervention': ['INTERVENTION 1: ', ' Single Arm', ' AZ6244: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15'], 'Eligibility': ['Inclusion Criteria:', ' Female breast cancer patient > 18 years.', ' Patients must have biopsy-proven clinical Stage Ic-III inv... | {'Clinical Trial ID': 'NCT01031446', 'Intervention': ['INTERVENTION 1: ', ' RAD001 and Cisplatin and Paclitazel', ' Cisplatin intravenously (IV) weekly for 3 weeks, then 1 week of rest; paclitaxel IV weekly for 3 weeks, then 1 week of rest. Everolimus (RAD001) po daily. One cycle = 4 weeks'], 'Eligibility': ['DISEASE... | 2f700407-8baf-4e5f-8fc0-378a294512f5 |
Single | Eligibility | NCT02287675 | Informed consent is optional for entry in the primary trial. | Contradiction | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT02287675', 'Intervention': ['INTERVENTION 1: ', ' Lymphoseek', ' Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | cebee448-235d-49ff-8e87-56639399548b | |
Single | Eligibility | NCT01073865 | Females over the age of 18, whose last period was 2 years prior to randomisation are eligible for the primary trial. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT01073865', 'Intervention': ['INTERVENTION 1: ', ' Zoladex 10.8 mg', ' ZOLADEX 10.8 mg (goserelin acetate): one subcutaneous depot injection into interior abdominal wall once every 12 weeks', 'INTERVENTION 2: ', ' Zoladex 3.6 mg', ' ZOLADEX 3.6 mg (goserelin acetate): one subcutaneous depot... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d3f0dd2f-a5b9-4ff4-8a6b-65c9947cb710 | |
Single | Adverse Events | NCT02187744 | sepsis, due to the presence of an implanted device was a common adverse event in the primary trial | Contradiction | [
0,
7
] | [] | {'Clinical Trial ID': 'NCT02187744', 'Intervention': ['INTERVENTION 1: ', ' PF-05280014', ' Participants received a loading dose of 8 mg/kg of PF-05280014 on Cycle 1 Day 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg. Taxotere 75 mg/m2 and carboplatin AUC 6 were administered on Day 1 of each cy... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7a981da3-dc7f-4e1f-ae5b-26e5399ba2a5 | |
Comparison | Eligibility | NCT00676793 | NCT01931163 | Patients with dysphagia cannot participate in the secondary trial, but may be eligible for the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [
0,
26
] | {'Clinical Trial ID': 'NCT00676793', 'Intervention': ['INTERVENTION 1: ', ' ECGC and Breast Cancer', ' Single arm for a phase II study of EGCG extract and breast cancer. Subjects are asked to take 4 polyphenol E (200mg) capsules daily with a meal for the duration of the study. Biomarkers are measured at baseline and ... | {'Clinical Trial ID': 'NCT01931163', 'Intervention': ['INTERVENTION 1: ', ' Everolimus Plus Cisplatin', ' Everolimus 10mg by mouth daily for 12 weeks; Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles'], 'Eligibility': ['Inclusion Criteria:', ' Female patients 18 years of age.', ' Cl... | af677d94-a376-42ea-93fe-91963a071199 |
Single | Eligibility | NCT00981305 | Only people who have previously been diagnosed with cancer and are currently receiving ongoing treatment for their primary tumor are eliglbe for the primary trial, as long as they are over the age of 20. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00981305', 'Intervention': ['INTERVENTION 1: ', ' Lactate-containing Vaginal Lubricant', ' apply 3cc of lactate-containing vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)', ' Lactate-containing vaginal lubricant: vaginal applying at least 3cc of ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6579e25e-8dcf-44b5-a50d-7c84672cba89 | |
Single | Adverse Events | NCT00451555 | Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT00451555', 'Intervention': ['INTERVENTION 1: ', ' Enzastaurin + Fulvestrant QD + BID', ' Participants received Enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 500 mg orally (QD) once daily in a 28-day cycle.', ' Participants received enzastaurin loadi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1ac9c526-91e6-4e0d-8570-0a78e3ec78db | |
Single | Adverse Events | NCT00767520 | Both cohorts of the primary trial reported the same precentage of patients vomiting during the trial. | Contradiction | [
0,
5,
13,
18
] | [] | {'Clinical Trial ID': 'NCT00767520', 'Intervention': ['INTERVENTION 1: ', ' Exemestane + Dasatinib', ' Oral dose of exemestane 25 mg + dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Exemestane + Placebo', ' Oral dose of exemestane 25 mg + placebo 100 mg, onc... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 79c07f36-daf9-4844-ad8a-f362fbbaaf81 | |
Single | Results | NCT01381874 | The Exemestane group in the primary trial had a better median Tumor Response than the Abiraterone Acetate + Prednisone group, however the patient with the maximum TR was in the Abiraterone Acetate + Prednisone group. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01381874', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Participants received exemestane tablet as oral dose of 25 milligram (mg) per day in 28-day treatment cycles until disease progression, unacceptable toxicity, or death (up to 3 years).', 'INTERVENTION 2: ', ' Abiraterone Aceta... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bced9c90-5ce0-416c-a168-f9e74359b332 | |
Comparison | Eligibility | NCT00593827 | NCT00478257 | Patients with HER2 negative BC are eligible for both the primary trial and the secondary trial. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00593827', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone 16 mg/m^2', ' ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest', 'INTERVENTION 2: ', ' Ixabepilone 40 mg/m^2', ' ixabepilone 40 mg/m^2 every 3 weeks'], 'Eligibility': ['Inclusion Criteria:', ' Has MBC that is me... | {'Clinical Trial ID': 'NCT00478257', 'Intervention': ['INTERVENTION 1: ', ' Effect of Bright Light', ' Effect of bright light on fatigue in women with breast cancer', 'INTERVENTION 2: ', ' Effect of Red Light', ' effect of red light on fatigue in women with breast cancer'], 'Eligibility': ['Inclusion Criteria:', ' ... | ce88c763-0062-48dc-b5e1-f81af32f2628 |
Single | Intervention | NCT00296036 | the primary trial administers the Urea/Lactic Acid Cream topically, twice daily, and the placebo is administered orally once a day. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00296036', 'Intervention': ['INTERVENTION 1: ', ' Urea/Lactic Acid Cream', ' Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily.', 'INTERVENTION 2: ', ' Placebo Cream', ' Patients receive placebo cream applied to palms and soles twice daily.'], 'El... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 982469a3-2fc1-40b4-92a9-d531b6c0ab5d | |
Comparison | Eligibility | NCT00334802 | NCT00167414 | There is no age limit for either the secondary trial or the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00334802', 'Intervention': ['INTERVENTION 1: ', ' Dose Level 1', ' Gemcitabine: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles', 'INTERVENTION 2: ', ' Dose Level 2', ' Gemcitabine: 1250 mg/m2, intravenous (IV), da... | {'Clinical Trial ID': 'NCT00167414', 'Intervention': ['INTERVENTION 1: ', ' Hypofractionated Stereotactic Body Radiation Therapy', ' Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionate... | 71d16ba8-2cc9-4cb0-aa14-6b6adf0dd625 |
Single | Results | NCT00143390 | In the primary trial There was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00143390', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal. The study treatment was continued until the disease progression or other discontinuation criteria were met.', 'INTERV... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e6901a45-4c97-4618-bfcb-6f6dd046ef0c | |
Single | Results | NCT00004888 | Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00004888', 'Intervention': ['INTERVENTION 1: ', ' Arm I: Doxorubicin and Taxotere', ' Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV, one hour after PLD completion, every 3 weeks for a total of 8 cycles. Dexamthasone 8 mg orally twice a day was administered the day bef... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e94ea1b1-1816-4bac-b1ca-f6d66b95702a | |
Comparison | Intervention | NCT01216319 | NCT03346161 | the secondary trial and the primary trial are evaluating surgical interventions for breast reconstruction for patients that have had mastectomies. | Contradiction | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01216319', 'Intervention': ['INTERVENTION 1: ', ' Nipple Reconstruction Cylinder', ' Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder'], 'Eligibility': ['Inclusion Criteria:', ' Patient presents with a history of breast cancer, having previously completed either uni- or bi-l... | {'Clinical Trial ID': 'NCT03346161', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: BREASTChoice (Decision Tool)', " Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, ... | 0e3c62f7-a152-4370-9d09-b69a715c0a21 |
Single | Results | NCT00410813 | In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00410813', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib, 100 mg, Daily', ' Dasatinib, 100 mg PO daily until progression of disease', 'INTERVENTION 2: ', ' Dasatinib, 70 mg, Twice Daily', ' Dasatinib, 70 mg PO twice daily until progression of disease'], 'Eligibility': ['DISEASE CHARACTE... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7191b5e9-4f29-4261-8a64-51653ee151fe | |
Single | Eligibility | NCT01597193 | ECOG > 1 and a life expectancy over 12 weeks are necessary to participate in the primary trial. | Contradiction | [
0,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01597193', 'Intervention': ['INTERVENTION 1: ', ' Dose Escalation: Enzalutamide 80 mg', ' Participants received enzalutamide 80 mg (two 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including a... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 639ccada-370d-4709-bdd7-1b29bbcc8769 | |
Single | Results | NCT02069093 | All of the patients in the primary trial had minimal Stomatitis symptoms and a normal diet. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT02069093', 'Intervention': ['INTERVENTION 1: ', ' Dexamethasone Based Mouthwash', ' Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or dri... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8c6e6c06-c409-4c42-b195-e9d2a1065b97 | |
Comparison | Adverse Events | NCT00191815 | NCT01301729 | None of the patients in the primary trial committed suicide, however there was one such case in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00191815', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine + Cisplatin', ' Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).', ' Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).'], 'Eligibility': ... | {'Clinical Trial ID': 'NCT01301729', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams p... | b5183c1c-adb5-4877-b061-50a16d6a5b52 |
Comparison | Results | NCT01855828 | NCT00696072 | the secondary trial uses Clinical Benefit (CBR) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01855828', 'Intervention': ['INTERVENTION 1: ', ' Chemo Plus Pertuzumab,Trastuzumab', ' During weeks 1-12, patients will receive pertuzumab, trastuzumab, and paclitaxel at the same time; during weeks 13-24 patients will receive pertuzumab and trastuzumab at the same time with 5-fluorouracil,... | {'Clinical Trial ID': 'NCT00696072', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib Plus Letrozole', ' Dasatinib + Letrozole: Tablets, Oral, once daily, up to 2 years', ' Dasatinib 100 mg + Letrozole 2.5 mg', ' Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable ... | 69f57cdb-22e9-4a3a-8f19-6095c66c6497 |
Comparison | Eligibility | NCT01771666 | NCT01256567 | Japanese participants with an ECOG <=1 are eligible for the secondary trial and the primary trial. | Entailment | [
0,
7
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01771666', 'Intervention': ['INTERVENTION 1: ', ' ISB and IC-Green Dye', ' The dose of Isosulfan blue (ISB) dye is 3 to 5 mL and Indocyanine green solution will be started at 1 mg/mL. If fluorescence is not detected with this dose, then it will be increased by 50%. A gamma probe [Neoprobe 20... | {'Clinical Trial ID': 'NCT01256567', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab and Docetaxel Combination', ' Docetaxel: Docetaxel administered by intravenous infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.', ' Ramucirumab: Ramucirumab administered as an intravenous infusion at a... | ea505463-c509-416e-ad88-11576764b734 |
Single | Adverse Events | NCT00930930 | The overall most frequent adverse event in the primary trial was Dehydration. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | [] | {'Clinical Trial ID': 'NCT00930930', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin and Paclitaxel + RAD001', ' Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO daily for 11 weeks', ' cisplatin: Given IV', ' everolimu... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 81669281-db01-4493-a797-0d60f448f706 | |
Comparison | Intervention | NCT00382785 | NCT00784849 | Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide, High Dose Magnesium Oxide or Mometasone in their intervention. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00382785', 'Intervention': ['INTERVENTION 1: ', ' Moderated Group', ' one 12-week online support group led by a professional healthcare provider', 'INTERVENTION 2: ', ' Non-facilitated (Peer-led)', ' 12-week online support in a peer-led format'], 'Eligibility': ['Inclusion Criteria: Clinic... | {'Clinical Trial ID': 'NCT00784849', 'Intervention': ['INTERVENTION 1: ', ' Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue', ' One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes'], 'Eligibility': ['Inclusion Criteria:', ' Stage 0,I, II breast cancer', ' Clinical nod... | 40dbf023-ead5-45fc-bdce-bf40e1955578 |
Single | Adverse Events | NCT00003782 | One of the cohorts in the primary trial had more than 5% of patients experiencing side effects. | Contradiction | [
0,
1,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00003782', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Doxorubicin + Cyclophosphamide, Then Docetaxel', ' Doxorubicin + Cyclophosphamide, then Docetaxel', 'INTERVENTION 2: ', ' Arm 2: Doxorubicin + Docetaxel', ' Doxorubicin + Docetaxel'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Hi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b64ae9c9-956a-421e-a41f-1886408fec2a | |
Comparison | Intervention | NCT01539317 | NCT01323530 | the primary trial uses a topical intervention and the secondary trial uses a combination of oral and intravenous treatments. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01539317', 'Intervention': ['INTERVENTION 1: ', ' Topical Saline', ' Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule', ' Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness', 'INTERVENTION 2:... | {'Clinical Trial ID': 'NCT01323530', 'Intervention': ['INTERVENTION 1: ', ' Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2)', ' Participants received eribulin mesilate 1.2 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day ... | e0980234-0611-44de-9165-54bdd086663d |
Single | Adverse Events | NCT00005908 | There were 8 cases of pharyngitis in cohort 2 of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00005908', 'Intervention': ['INTERVENTION 1: ', ' Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine', ' Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles Once the dose was deemed to be too toxic, subsequent patients were enrolled on dose B.... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3366c10a-3d41-48ae-bfa8-26b9e655761e | |
Single | Adverse Events | NCT01572727 | Cohort 1 of the primary trial recorded more white blood cell related adversse events than cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT01572727', 'Intervention': ['INTERVENTION 1: ', ' BKM120 and Paclitaxel', ' Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel', 'INTERVENTION 2: ', ' Placebo and Paclitaxel', ' Adult females with histolo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | be29030a-98e8-40ad-9138-90076fdb50d3 | |
Single | Results | NCT01097460 | Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT01097460', 'Intervention': ['INTERVENTION 1: ', ' MM-111 + Herceptin', ' MM-111 will be combined with Herceptin', ' MM-111 and Herceptin: For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV'], 'Eligibility': ['Inclusion Criteria:', ' Patie... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a31298d5-20ae-4a3d-a57b-e97288fff6c0 | |
Single | Adverse Events | NCT00003830 | The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected less than 1% of patients. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00003830', 'Intervention': ['INTERVENTION 1: ', ' Arm I:Sentinel Node Resection+Conventional Axillary Dissection', ' Sentinel node resection immediately followed by axillary dissection', ' conventional surgery: Sentinel node resection immediately followed by axillary dissection.', 'INTERVEN... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 54e93334-0f21-4ea2-b0f2-34473385da53 | |
Single | Eligibility | NCT00404066 | Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial. | Entailment | [
22,
28,
29
] | [] | {'Clinical Trial ID': 'NCT00404066', 'Intervention': ['INTERVENTION 1: ', ' Neoadjuvant Chemotherapy', ' Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles, followed by docetaxel + lapatinib for four 21-day cycles, followed by surger... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fbedd8fc-05e8-4438-b780-d7483aed3b45 | |
Single | Results | NCT01202591 | 100% of patients in the primary trial suffered life threatening adverse events. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01202591', 'Intervention': ['INTERVENTION 1: ', ' AZD4547 80mg bd Cont + Ex 25mg', ' 80 mg AZD4547 BD continuous + 25 mg exemestane', 'INTERVENTION 2: ', ' AZD4547 40mg Cont + Ex 25mg', ' 40 mg AZD4547 BD continuous + 25 mg exemestane'], 'Eligibility': ['Inclusion Criteria:', ' Post-menop... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4bd9f061-6420-443d-8f84-b703733644ac | |
Single | Intervention | NCT00046891 | cohort 1 of the primary trial recieves 120 mg of Ginkgo Biloba twice daily. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00046891', 'Intervention': ['INTERVENTION 1: ', ' Ginkgo Biloba', ' Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID)', 'INTERVENTION 2: ', ' Placebo', ' Placebo: Patients will take 1 tablet BID'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Newly diagnosed breast cancer', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e6d3354b-b36a-42b9-b406-61a9af594686 | |
Single | Eligibility | NCT00896649 | prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT00896649', 'Intervention': ['INTERVENTION 1: ', ' Single Arm Positron Emission Mammography and Questionnaire', ' questionnaire administration positron emission mammography', ' digital mammography: standard screening mammogram', ' questionnaire administration: Questionnaire regarding patien... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 62b3d09e-6b2a-4827-8ceb-96ccafca18d4 | |
Single | Eligibility | NCT00317603 | Participants of the primary trial must be older than 18, have histologically confirmed stage 3 or above breast cancer, ECOG<2 and a life expectancy exceeding 6 months. | Contradiction | [
0,
1,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT00317603', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 065a6cfe-3991-4dd5-8a55-22b9b31d1fc3 | |
Comparison | Intervention | NCT00278109 | NCT01881230 | Gemcitabine is not used in the primary trial, and used in only one of the arms of the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00278109', 'Intervention': ['INTERVENTION 1: ', ' Experimental', ' cyclophosphamide: chemotherapy', ' doxorubicin hydrochloride: chemotherapy', ' adjuvant therapy: chemotherapy', ' radiation therapy: chemotherapy'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed a... | {'Clinical Trial ID': 'NCT01881230', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Nab-Paclitaxel + Gemcitabine', ' Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle... | 85c315e5-7ae4-4764-8b02-87d36f67a159 |
Single | Adverse Events | NCT01560416 | There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial. | Entailment | [
0,
1,
12,
13
] | [] | {'Clinical Trial ID': 'NCT01560416', 'Intervention': ['INTERVENTION 1: ', ' ARM A - Fulvestrant', ' Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Eligible participants on Arm A were allowed to crossover to... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 497188e0-9d88-406f-b163-c154516cb12c | |
Comparison | Eligibility | NCT00438100 | NCT00662025 | Patients with BUN < 20 mg/dL, Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00438100', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine Arm', ' Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.', ' Capecitabine: 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day was... | {'Clinical Trial ID': 'NCT00662025', 'Intervention': ['INTERVENTION 1: ', ' SUNITINIB+CAPECITABINE', ' Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles. Capecitabine was administered orally from Days 1 to 14 every 21 days at a star... | abc437e1-9e38-4d68-ab9f-fdbaf37d20f3 |
Comparison | Adverse Events | NCT01828021 | NCT01326481 | Patients in the primary trial and the secondary trial did not have any of the same adverse events, except Supraventricular extrasystoles which was the most common event in both trials. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT01828021', 'Intervention': ['INTERVENTION 1: ', ' Margetuximab', ' Monotherapy of Anti-HER2 monoclonal antibody', ' Margetuximab: Anti-HER2 monoclonal antibody'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed invasive carcinoma of the breast', ' Treatm... | {'Clinical Trial ID': 'NCT01326481', 'Intervention': ['INTERVENTION 1: ', ' Carotuximab (TRC105) Plus Capecitabine', ' All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)'], 'Eligibility': ['Inclusion Criteria:', ' Histologically proven advanced solid ... | f26fb90b-a9a5-4614-9680-2e9f6f0ba649 |
Single | Eligibility | NCT00388726 | A 75 year old female patient, with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for the primary trial. | Entailment | [
0,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00388726', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/kg^2', ' Eribulin Mesylate 1.4 mg/kg^2 on Days 1 and 8', 'INTERVENTION 2: ', " Treatment of Physician's Choice", " Treatment of Physician's Choice"], 'Eligibility': ['Inclusion Criteria:', ' Female patients with hi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 90dd042b-c16c-4ea7-b360-625bd5e64590 | |
Single | Results | NCT01271725 | In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 13% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01271725', 'Intervention': ['INTERVENTION 1: ', ' Afatinib Monotherapy', ' Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Pati... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9b03c9e7-ca64-4e9f-9c10-f8c2d64ff0b7 | |
Comparison | Eligibility | NCT00915603 | NCT02511730 | INR equal to or above 1.5 is mandatory for participation in the primary trial, it is not necessary for the secondary trial. | Entailment | [
0,
24
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00915603', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel/Bevacizumab/Everolimus', 'Systemic Therapy', 'INTERVENTION 2: ', ' Paclitaxel/Bevacizumab/Placebo', 'Systemic Therapy'], 'Eligibility': ['Inclusion Criteria:', ' Female or male patients >=18 years of age.', ' Histologically confi... | {'Clinical Trial ID': 'NCT02511730', 'Intervention': ['INTERVENTION 1: ', ' FFDM Plus DBT', ' Breast Images with FFDM and DBT', ' FFDM Plus DBT: Fujifilm Aspire Cristalle System', 'INTERVENTION 2: ', ' FFDM', ' Breast Images with FFDM alone', ' FFDM: Fujifilm Aspire Cristalle System'], 'Eligibility': ['Inclusion ... | 20cc98f8-a71a-466d-a39c-735899791613 |
Single | Adverse Events | NCT00391092 | In total there were 32 cases of Febrile neutropenia in the primary trial. | Entailment | [
0,
2,
12,
14
] | [] | {'Clinical Trial ID': 'NCT00391092', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Docetaxel', " Trastuzumab 8 mg/kg loading dose administered intravenously on Day 1 of Cycle 1, followed by docetaxel 100 mg/m^2 on Day 2 of Cycle 1. Then a maintenance dose of trastuzumab at 6 mg/kg and docetaxel at 100 mg/m^2 w... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fa1c6f63-ae37-4c18-918b-7b9ba445fd81 | |
Comparison | Intervention | NCT00194779 | NCT04080297 | IV is used as route of administration by the interventions in the primary trial and the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00194779', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Neoadjuvant Therapy, Adjuvant Therapy)', ' See Detailed Description.', ' doxorubicin hydrochloride: Given IV', ' cyclophosphamide: Given PO', ' paclitaxel: Given IV', ' filgrastim: Given SC', ' capecitabine: Given PO', ' meth... | {'Clinical Trial ID': 'NCT04080297', 'Intervention': ['INTERVENTION 1: ', ' 100 mg Q-122', ' Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.', 'INTERVENTION 2: ', ' 200 mg Q-122', ' Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.']... | 6d0b2acc-11f4-479f-9a86-004e2f5f7599 |
Comparison | Intervention | NCT02352779 | NCT00263588 | The differences between cohorts in the primary trial is once cohort recieves a placebo and the other Low-dose Omega-3 Fatty Acid, in contrast the difference in the secondary trial is patient characteristics. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT02352779', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Low-dose Omega-3 Fatty Acid)', ' Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.', 'Omega-3 Fatty Acid: Given PO', ' Placebo: Given PO', ' Questionnaire Administration: Ancillary st... | {'Clinical Trial ID': 'NCT00263588', 'Intervention': ['INTERVENTION 1: ', ' Cohort A', ' 750mg lapatinib administered orally twice daily. Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens, in total, for treatment of breast canc... | 7e9c3980-9f12-40c7-920e-76594db26fd1 |
Comparison | Eligibility | NCT00499083 | NCT03045653 | In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 negative breast cancer. | Entailment | [
6,
10,
12
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00499083', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Patients with HER-2/neu negative tumors received therapeutic autologous dendritic cells: injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.', ' Adjuvant hormo... | {'Clinical Trial ID': 'NCT03045653', 'Intervention': ['INTERVENTION 1: ', ' Treatment Arm', ' receiving a treatment of tamoxifen 100 mg/d'], 'Eligibility': ['Inclusion Criteria:', ' - Female 18 years, 70 years. ECOG 0-1 with no deterioration over previous 2 weeks Minimum life expectancy 3 months Histological confir... | c83e003d-d12d-4f72-ab1f-c39f3a13326b |
Single | Adverse Events | NCT00244933 | the primary trial monitors the occurrence of anemia in its adverse events. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00244933', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine & Genistein', ' Gemcitabine, genistein (Novasoy), Tumor biopsy Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days: Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.'], 'Eligibility': ['DISEASE C... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | cae58656-76e7-447a-940e-dfcc78159173 | |
Single | Adverse Events | NCT02481050 | There are no adverse events in the primary trial that occurred more than once. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT02481050', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/m^2', ' Participants with histologically confirmed HER2-negative MBC who were previously treated with 2 to 5 chemotherapy regimens received eribulin mesylate 1.4 mg/m^2, intravenous infusion over 2 to 5 minutes on Day... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 94c4c3fc-7bcb-407b-86b5-6699305d3dbd | |
Single | Adverse Events | NCT00022516 | At most 3 patients in the primary trial suffered from Neutropenia. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | [] | {'Clinical Trial ID': 'NCT00022516', 'Intervention': ['INTERVENTION 1: ', ' No-CM', ' No further chemotherapy following standard adjuvant chemotherapy.', 'INTERVENTION 2: ', ' CM-Maintenance', ' 12-month CM-maintenance regimen (C, cyclophosphamide 50 mg/day orally continuously and M, methotrexate 2.5 mg twice/day o... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 103fbaa8-1852-402a-9368-36bbf6c747b2 | |
Single | Eligibility | NCT00581256 | Patients with left-sided breast cancer and an ECOG of 3 are excluded from the primary trial. | Entailment | [
0,
4,
8,
14,
17
] | [] | {'Clinical Trial ID': 'NCT00581256', 'Intervention': ['INTERVENTION 1: ', ' IMRT', ' Best Delivery-optimized radiotherapy technique (IMRT)', ' IMRT: All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 731dc36f-983d-4d4c-97ac-6e3eeee23a40 | |
Single | Intervention | NCT00429299 | Only one cohort in the primary trial is administered trastuzumab at 4 milligrams per kilogram. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT00429299', 'Intervention': ['INTERVENTION 1: ', ' CT Plus Trastuzumab', ' Participants received chemotherapy (CT), which included paclitaxel 80 milligrams per meters squared (mg/m^2) weekly for 12 weeks, followed by intravenous (IV) fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and I... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b2883781-f4e9-405e-9231-7a07e46c35b0 | |
Comparison | Intervention | NCT00791037 | NCT00606931 | the primary trial and the secondary trial both use vaccine based interventions, however this is done in different intervals and for a different duration of time. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00791037', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Vaccine Therapy+ex Vivo-expanded T Cells)', ' Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later, patients undergo leukapheresis to isolate and collect peri... | {'Clinical Trial ID': 'NCT00606931', 'Intervention': ['INTERVENTION 1: ', ' PET Guided Biopsy', ' No comparison group. All enrolled participants were expected to undergo PET guided biopsy.'], 'Eligibility': ['Inclusion Criteria:', ' Individuals aged 25 years or older', ' Individuals who have at least one breast ima... | 932c2135-381a-4675-a782-e683eca8d935 |
Comparison | Results | NCT01648322 | NCT00436566 | the primary trial has a shorter time frame than the secondary trial. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01648322', 'Intervention': ['INTERVENTION 1: ', ' 80 µg/kg/Dose of F-627(TC)', ' This dose of F-627 given only to subjects that are to have TC chemotherapy.', ' F-627: subcutaneous injection given 1 per chemotherapy.', 'INTERVENTION 2: ', ' 240 µg/kg/Dose of F-627 (TC)', ' This dose of F-... | {'Clinical Trial ID': 'NCT00436566', 'Intervention': ['INTERVENTION 1: ', ' AC/PTL', ' Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to... | 6461007d-fc18-43e2-a797-11cb0a4512ce |
Comparison | Eligibility | NCT00630032 | NCT00428922 | Patients with radiologically confirmed metatases in the CNS are excluded from both the secondary trial and the primary trial. | Entailment | [
13,
14
] | [
6,
7
] | {'Clinical Trial ID': 'NCT00630032', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel', ' 3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of D (100 mg/m² every 3 weeks)', ' Cyclophosphamide: 500 mg/m² every 3 weeks Docetaxel: 100 mg/m² every 3 weeks Epirubicin hydroch... | {'Clinical Trial ID': 'NCT00428922', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Bevacizumab, and Docetaxel', ' Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed breast cancer with evidence of metastatic disease', ' HER... | 819e85b0-2d4e-4535-b920-4e18868da883 |
Single | Results | NCT03098550 | There results from cohort 3 of the primary trial were inconclusive. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT03098550', 'Intervention': ['INTERVENTION 1: ', ' Nivolumab + Daratumumab (TNBC)', ' Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | cc0d6fe8-69c4-49d3-b321-00e47c155db6 | |
Single | Adverse Events | NCT00454532 | Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00454532', 'Intervention': ['INTERVENTION 1: ', ' Level 1', '10g/day', 'INTERVENTION 2: ', ' Level 2', '20g/day'], 'Eligibility': ['Key Inclusion Criteria:', ' Women 18 years or older', ' Histologically confirmed breast cancer', ' Clinical evidence of metastatic (stage IV) metastasis (oth... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0fbb4fb4-620b-4ee9-aaa8-956992026cef | |
Single | Results | NCT02679755 | Every patient in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events. | Entailment | [
0,
1,
2,
3,
14,
15,
16,
17,
8,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT02679755', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib+Letrozole India Cohort', ' Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle. Participants received Letrozole orally at 2.5 mg once daily as continuous... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 69b12ff4-6bb4-4207-b400-67795709c3c8 | |
Single | Eligibility | NCT00829166 | Female patients with Peripheral neuropathy grade 3 or 4 are excluded from the primary trial. | Entailment | [
9,
12
] | [] | {'Clinical Trial ID': 'NCT00829166', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' Participants received trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9c0b258d-1e66-4eaa-b4e7-a9098eaed1d7 | |
Single | Eligibility | NCT00464646 | Anna is a 57 year old female with an ECOG of 0, diagnosed with an invasive adenocarcinoma of the breast, IHC results were 1+. She is eligible for the primary trial. | Contradiction | [
0,
15,
16,
17,
18,
19,
10
] | [] | {'Clinical Trial ID': 'NCT00464646', 'Intervention': ['INTERVENTION 1: ', ' Cohort A', ' Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)', 'INTERVENTION 2: ', ' Cohort B', ' Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer'], 'Eligibili... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9872cf9f-6f43-44d3-97ce-e205e0e5fc6c | |
Comparison | Adverse Events | NCT00623233 | NCT01525589 | the primary trial recorded 1 patient with a deficiency of platelets in the blood, whereas a total of 6 patients with a platelet deficiency where found in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT00623233', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg', ' Gemcitabine 2500 milligrams per square meter (mg/m^2) intravenous (IV) over 30 minutes given on Day 1 every 14 days (q 14 days) until disease progression (PD) or unacceptable toxicity.', ' B... | {'Clinical Trial ID': 'NCT01525589', 'Intervention': ['INTERVENTION 1: ', ' Cohort A (BRCA+)', ' Patients with known deleterious BRCA1/2 mutation status at study entry', 'INTERVENTION 2: ', ' Cohort A1 (BRCA+/PARPi)', ' Patients with known deleterious BRCA1/2 mutation status and prior treatment with PARPi.'], 'Elig... | efc15257-5e19-4b7e-8b51-da94840784d8 |
Comparison | Adverse Events | NCT01310231 | NCT00093808 | 19.57% of patients in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT01310231', 'Intervention': ['INTERVENTION 1: ', ' Metformin', ' Metformin plus standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).', ' Metformin: metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, pla... | {'Clinical Trial ID': 'NCT00093808', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine + Vinorelbine + Trastuzumab', ' Treatment followed a 21-day cycle. Capecitabine was administered orally twice daily at a dose of 825 mg/m^2 on days 1 to 14, vinorelbine was administered intravenously (IV) at a dose of 25 mg/m^2 o... | 0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1 |
Single | Adverse Events | NCT02129556 | Cohort 1 of the primary trial had a much higher number of deaths than cohort 2. | Contradiction | [
0,
10,
13,
23
] | [] | {'Clinical Trial ID': 'NCT02129556', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib 2 mg/kg', ' HER2-positive, PD-L1 expressing, unresectable loco-regional or metastatic breast carcinoma that progressed on prior trastuzumab-based therapy', 'INTERVENTION 2: ', ' Phase Ib 10 mg/kg', ' HER2-positive, PD-L1 expressing... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7990b9bf-ac76-4f21-b9a1-5e0b4d91b9a9 | |
Single | Intervention | NCT01819233 | All the primary trial participants must reduce the number of calories in their diets by a quarter throughout the duration of the study. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT01819233', 'Intervention': ['INTERVENTION 1: ', ' Behavioral Dietary Intervention', ' Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric inta... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e4961c1a-83e2-40ed-93ac-64d5cef1f84a | |
Comparison | Eligibility | NCT01663727 | NCT00072293 | There is no maximum or minimum age defined for participation in the primary trial or the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18
] | [
16,
17,
18
] | {'Clinical Trial ID': 'NCT01663727', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel+Placebo', ' Participants received paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.', 'INT... | {'Clinical Trial ID': 'NCT00072293', 'Intervention': ['INTERVENTION 1: ', ' Axillary Dissection', ' Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.', ' Axillary lymph node dissection: Axillary lymph node dissection', 'INTERVENTION... | 9cb1c975-0d49-4437-af56-1a4f97e30aef |
Single | Eligibility | NCT02732119 | Mark suffered Refractory ventricular fibrillation twice in the last month he is therefore excluded from the primary trial. | Entailment | [
8,
14
] | [] | {'Clinical Trial ID': 'NCT02732119', 'Intervention': ['INTERVENTION 1: ', ' Cohort A', ' Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B', 'INTERVENTION 2: ', ' Cohort B', ' Ribociclib (300 mg daily), everolimus ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 51699ae8-d297-4635-95c1-4ed38c8706c3 | |
Single | Eligibility | NCT02756364 | In order to meet the inclusion criteria for the primary trial patients must have had ineffective aromatase inhibitor (AI) therapy before study entry, | Entailment | [
0,
9
] | [] | {'Clinical Trial ID': 'NCT02756364', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Fulvestrant 500 mg', ' Fulvestrant 500 mg, intramuscularly (IM), once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median dur... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c2c73b99-f89c-4dd3-8362-295f9a7965f3 | |
Single | Adverse Events | NCT02129556 | Cohort 1 of the primary trial had a much higher mortality rate than cohort 2. | Entailment | [
0,
10,
13,
23
] | [] | {'Clinical Trial ID': 'NCT02129556', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib 2 mg/kg', ' HER2-positive, PD-L1 expressing, unresectable loco-regional or metastatic breast carcinoma that progressed on prior trastuzumab-based therapy', 'INTERVENTION 2: ', ' Phase Ib 10 mg/kg', ' HER2-positive, PD-L1 expressing... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 180d7b66-9ee9-40fb-b4c7-a6060e6f67b7 | |
Comparison | Adverse Events | NCT00394082 | NCT01033032 | the primary trial recorded cases of Anaphylaxis and Spinal compression fracture, neither of these were observed in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT00394082', 'Intervention': ['INTERVENTION 1: ', ' ABI-007 Plus Bevacizumab', ' ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If... | {'Clinical Trial ID': 'NCT01033032', 'Intervention': ['INTERVENTION 1: ', ' Amrubicin', ' Systemic therapy with amrubicin'], 'Eligibility': ['Inclusion Criteria:', ' Females >=18 years of age.', ' Histologic diagnosis of HER2-negative breast cancer. HER-2 negativity must be confirmed by one of the following:', ' F... | 949ac54b-a871-4134-a507-c98a4de55720 |
Single | Eligibility | NCT00167414 | Patients must have Human epidermal growth factor receptor 2 (HER2) overexpressive tumors to participate in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT00167414', 'Intervention': ['INTERVENTION 1: ', ' Hypofractionated Stereotactic Body Radiation Therapy', ' Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionate... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 02407f87-235d-4240-98fe-498b352cce75 | |
Single | Eligibility | NCT00030823 | Patients with stage I, II, III or IV triple negative breast cancer are not eliglbe for the primary trial. | Contradiction | [
12,
13
] | [] | {'Clinical Trial ID': 'NCT00030823', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Diagnosis of breast ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 61a524d4-1697-4a10-b36a-a0c6cda79526 | |
Single | Eligibility | NCT01597193 | ECOG < 2 and a life expectancy over 12 weeks are necessary to participate in the primary trial. | Entailment | [
0,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01597193', 'Intervention': ['INTERVENTION 1: ', ' Dose Escalation: Enzalutamide 80 mg', ' Participants received enzalutamide 80 mg (two 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including a... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 304977b6-9742-4c3b-84fd-e5ef1737a143 | |
Single | Eligibility | NCT01790932 | patients with Phosphoinositide 3-kinase inhibitor based treatments are ineligible for the primary trial | Entailment | [
5,
6
] | [] | {'Clinical Trial ID': 'NCT01790932', 'Intervention': ['INTERVENTION 1: ', ' BKM120', ' BKM120: 100 mg capsule once daily each day of a 28 day cycle .', ' Treatment with BKM120 will continue until disease progression, unacceptable toxicity or withdrawal for other reasons.'], 'Eligibility': ['Inclusion Criteria:', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 87c65217-85d9-4f05-87aa-f4dfacd9f25a | |
Comparison | Intervention | NCT01385137 | NCT00593346 | Placebo treatment is used in the secondary trial, but there is only a test group in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01385137', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Omega-3-fatty Acid)', ' Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Arm II (Placebo)', ' Pa... | {'Clinical Trial ID': 'NCT00593346', 'Intervention': ['INTERVENTION 1: ', ' Accelerated Partial Breast Brachytherapy', ' Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.', ' Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given o... | 19e89ebc-a417-47a8-bfa7-1778baead178 |
Comparison | Adverse Events | NCT00950300 | NCT00615901 | the primary trial recorded a patient with chest pain, whereas the secondary trial observed a patient with abdominal pain. | Entailment | [
0,
10
] | [
0,
3
] | {'Clinical Trial ID': 'NCT00950300', 'Intervention': ['INTERVENTION 1: ', ' Herceptin IV + Chemotherapy', ' Participants received eight cycles of Herceptin IV plus chemotherapy prior to surgery and ten cycles of Herceptin IV after surgery. Chemotherapy consisted of docetaxel 75 mg/m^2 every 21 days for four cycles fo... | {'Clinical Trial ID': 'NCT00615901', 'Intervention': ['INTERVENTION 1: ', ' Cohort A (CMF at 14 Day Intervals)', ' This is a pilot study using 8 cycles of CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2), at 14 day intervals supported by PEG-filgrastim for a cohort of 38 patients. A... | 561a0631-1eb3-48d1-baa2-81eb3fa79b98 |
Single | Adverse Events | NCT01671319 | 1/42 patients in cohort 1 of the primary trial fainted. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01671319', 'Intervention': ['INTERVENTION 1: ', ' Dose Dense TC + Pegfilgrastim', ' Docetaxel + Cyclophosphamide chemotherapy given every 2 weeks x 4 cycles plus pegfilgrastim given 24-48 hours post day 1 of each cycle', ' docetaxel + cyclophosphamide + pegfilgrastim: docetaxel 75 mg/m2 + c... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bc617e84-a0c1-400b-9ad5-88b56d1805e8 | |
Single | Eligibility | NCT01097642 | Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T3 N1 M0) are eligible for the primary trial. | Entailment | [
0,
1,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01097642', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone', ' Brand name is Ixempra ®; it is an epothilone B analog used in combination with other chemotherapeutics against cancer.', ' Ixabepilone: Ixabepilone will be given at 40mg/m^2 IV over 180 minutes on day 1 of each of four 21 day... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8a8b7b19-9328-4cb3-b01c-8f4c358f4ac5 | |
Single | Intervention | NCT00354640 | Patients taking Intervention 1 of the primary trial receive higher doses of anastrozole than of simvastatin. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00354640', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole and Simvastatin', ' adjuvant therapy : laboratory analysis', ' pharmacological study : laboratory analysis', ' simvastatin : 40 milligram tablet PO QD for 14 days', ' anastrozole : 1 milligram tablet PO QD for 14 days'], 'Eligi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bb4f69b0-0e2e-44e6-a3b6-049f4a8505fe | |
Single | Adverse Events | NCT00148668 | Cohort 1 and 2 of the primary trial recorded the same number of patients with Febrile Neutropenia. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00148668', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Herceptin/navelbine', 'INTERVENTION 2: ', ' Arm 2', ' Taxotere/carboplatin/herceptin'], 'Eligibility': ['Inclusion Criteria:', ' Patients with stage II or III breast cancer', ' HER-2 positive tumors', ' Older than 18 years of a... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b059e44b-9830-4c45-858e-ebd007fbaf69 | |
Single | Eligibility | NCT00436917 | Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial, as these would interfere with the necessary CT and MRI scans for the study. | Contradiction | [
39,
40,
41
] | [] | {'Clinical Trial ID': 'NCT00436917', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid', ' 4 mg intravenously over 15 minutes every 6 months (until disease progression or for 5 years)'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Diagnosis of localized breast cancer', ' Stage I-IIIA disease', ' Adequately ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fec065ca-fbde-476d-ab0d-7e7054e29858 | |
Comparison | Intervention | NCT01153672 | NCT01432145 | Patients in the primary trial receive vorinostat at the same frequency, dosage and through the same route of administration as the secondary trial receive 6-Mercaptopurine. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01153672', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Enzyme Inhibitor Therapy, AI Sensitization Therapy)', ' Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 wee... | {'Clinical Trial ID': 'NCT01432145', 'Intervention': ['INTERVENTION 1: ', ' 6-Mercaptopurine and Methotrexate (6MP/MTX)', ' 6-Mercaptopurine: 6MP 75mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given c... | ea3bd229-001c-487f-9cda-edf2e699dbb2 |
Comparison | Eligibility | NCT00297596 | NCT00580333 | Patients have received prior radiation treatment, to treat the current breast cancer, in the last two 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial. | Contradiction | [
0,
8,
10
] | [
8,
9
] | {'Clinical Trial ID': 'NCT00297596', 'Intervention': ['INTERVENTION 1: ', ' Oxaliplatin/Trastuzumab', ' Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mg/m2 IV day 1 and trastuzumab 6 mg/kg (following 8 mg/kg loading dose during cycle 1). Cycles were repeated every 21 days. Oxalipla... | {'Clinical Trial ID': 'NCT00580333', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin/Avastin', ' Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)', ' cisplatin: Preopera... | 576e519a-1ef3-43e5-a13c-6058ad71f388 |
Single | Intervention | NCT03374995 | the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT03374995', 'Intervention': ['INTERVENTION 1: ', ' Group I (Topical Keratin)', ' Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks).', ' Quality-of-Life Assessment: Ancillary studies', ' Topical Keratin: Given topically', 'IN... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 699d0cb5-1ebb-441d-aa7e-041a48923b00 | |
Single | Eligibility | NCT01127373 | Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumors are eliglbe for the primary trial. | Entailment | [
0,
5
] | [] | {'Clinical Trial ID': 'NCT01127373', 'Intervention': ['INTERVENTION 1: ', ' Radiation Therapy Via Multi-beam IMRT', ' This is a single-arm feasibility study of multi-beam IMRT with daily set-up verification in the treatment of women with node-positive breast cancer who will receive radiation to the breast/chest wall ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6ec27be7-aa61-4ba8-b92a-98dcaee1eb0b | |
Single | Adverse Events | NCT00266799 | None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or acute coronary syndrome. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT00266799', 'Intervention': ['INTERVENTION 1: ', ' Pegylated Liposomal Doxorubicin (PLD)', ' PLD 50 mg/m^2 was administered intravenously once every 28 days. Each cycle was repeated until progress or unacceptable toxicity.', 'INTERVENTION 2: ', ' Capecitabine', ' Capecitabine 1250 mg/m^2, i... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6e882de6-e55f-40a4-95a1-bdb176e68a18 | |
Single | Eligibility | NCT00834678 | Patients with lymphopenia can participate in the primary trial. | Contradiction | [
18
] | [] | {'Clinical Trial ID': 'NCT00834678', 'Intervention': ['INTERVENTION 1: ', ' Bendamustine and Erlotinib', ' Participants in dose level I were administered 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.', ' Participants in dose level II were administered 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 525ed182-07e9-4548-87b3-c831e0b7389e | |
Comparison | Adverse Events | NCT00110084 | NCT01961544 | the primary trial and the secondary trial both reported cases of Pseudomonal sepsis in their patients. | Contradiction | [
0,
10
] | [
0,
12
] | {'Clinical Trial ID': 'NCT00110084', 'Intervention': ['INTERVENTION 1: ', ' Nab-paclitaxel/Gemcitabine', ' Nab (nanoparticle albumin-bound)-Paclitaxel (125mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle and gemcitabine (1000 mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle'], 'Eligibility': ['DISEASE CHA... | {'Clinical Trial ID': 'NCT01961544', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/m^2', ' Participants received 1.4 milligrams per meters squared (mg/m^2) eribulin mesylate intravenously over the course of 2 to 5 minutes on Day 1 and Day 8 of each 21-day cycle.'], 'Eligibility': ['Inclusion Criteri... | 233d2ec1-1383-4088-90af-c5a948847631 |
Single | Adverse Events | NCT00426556 | There were an equal number of cases of Febrile neutropenia, Leukopenia and Neutropenia across cohorts in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
14,
15,
16,
17,
18
] | [] | {'Clinical Trial ID': 'NCT00426556', 'Intervention': ['INTERVENTION 1: ', ' Phase I - RAD001 5mg + PT, Daily', ' Daily dosing schedule of Everolimus 5mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab', 'INTERVENTION 2: ', ' Phase I - RAD001 10mg + PT, Daily', ' Daily dosing schedule of Everolimus 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8e3fe244-d47d-48ce-ab29-4a5226024aad | |
Single | Eligibility | NCT00005957 | T4 N3 M0 adenocarcinoma of the breast are eligible for the primary trial. | Contradiction | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00005957', 'Intervention': ['INTERVENTION 1: ', ' Standard Breast Irradiation', ' radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.', 'INTERVENTION 2: ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 670443b0-89bf-4af4-a9ab-4cdff26d09a8 | |
Comparison | Intervention | NCT00332709 | NCT00659373 | All the primary trial participants receive the same dose of Letrozole, only certain patients in the secondary trial are administered Exemestane. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT00332709', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Letrozole 2.5 mg/day for 3 years', 'INTERVENTION 2: ', ' Letrozole + Zoledronic Acid', ' Letrozole 2.5mg/day for 3 years plus Zoledronic acid 4mg every 6 months'], 'Eligibility': ['Inclusion Criteria:', ' Compliant postmenopa... | {'Clinical Trial ID': 'NCT00659373', 'Intervention': ['INTERVENTION 1: ', ' Tamoxifen', ' Tamoxifen 20mg orally daily for 5 years', 'INTERVENTION 2: ', ' Ovarian Function Suppression', ' Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH... | 455748bf-8e12-4834-8126-ab77cab16200 |
Single | Results | NCT01808573 | the primary trial Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval) Progression Free Survival more than 2 months longer than patients administered with Lapatinib Plus Capecitabine. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01808573', 'Intervention': ['INTERVENTION 1: ', ' Neratinib Plus Capecitabine', ' neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d29bd9dd-b52e-4b18-82ea-e2914dfb9579 | |
Single | Results | NCT00337103 | The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00337103', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/m^2', ' Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.', 'INTERVENTION 2: ', ' Capecitabine 2.5 g/m^2/Day', ' Capecitabine : Capecitabine 2.5 g/m^2/day a... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2649c857-f98d-4529-9a4a-4f8b17813cb8 | |
Single | Results | NCT00399802 | The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00399802', 'Intervention': ['INTERVENTION 1: ', ' Single IV Infusion of ZA 4 mg', ' Participants received a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks.', 'INTERVENTION 2: ', ' Once-daily Odanacatib 5 mg', ' Partic... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0a6e8720-ea47-4520-bd02-e0eb8fcd880f | |
Single | Results | NCT02679755 | More patients in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events compared to patients in the Palbociclib+Letrozole India Cohort. | Contradiction | [
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT02679755', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib+Letrozole India Cohort', ' Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle. Participants received Letrozole orally at 2.5 mg once daily as continuous... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ce6630d3-d3b7-4870-a486-9b6284a454f0 | |
Comparison | Intervention | NCT00054028 | NCT02162719 | Both the primary trial and the secondary trial at least partly administer their interventions intravenously. | Entailment | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00054028', 'Intervention': ['INTERVENTION 1: ', ' Suramin and Paclitaxel', ' Suramin will be infused weekly over 30 minutes. Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin.'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have h... | {'Clinical Trial ID': 'NCT02162719', 'Intervention': ['INTERVENTION 1: ', ' Ipatasertib and Paclitaxel', ' Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, in... | 27e31574-5a73-4a68-997d-daa84797a65a |
Single | Adverse Events | NCT00014222 | Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded 41. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00014222', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: CEF', ' 6 cycles - q 28 days (6 months) - Cyclophosphamide 75 mg/m2 - po - Days 1-14 - Epirubicin 60 mg/m2 - IV - Days 1 and 8 - 5 Fluorouracil: 500mg/m2 - IV - Days 1 and 8 + Continuous Antibiotic Prophylaxis with Cotrimoxazole 960 mg... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e21171de-ad49-4fc5-9c5d-aa362ca61c8a | |
Single | Intervention | NCT02518191 | Cohort 2 of the primary trial is the control group, as the Eligible patients with breast cancer treated with GnRHa every 28 days. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT02518191', 'Intervention': ['INTERVENTION 1: ', ' GnRHa (Gonadotrophin-releasing Hormone Analogues) Group', ' Eligible patients with breast cancer treated with GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy.', ' Goserelin 3.6mg, or leuprorelin 3.75mg subcutan... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5dcdeac8-1c4a-4c24-9074-bbe93fcf4d32 | |
Single | Results | NCT00684983 | The Median length of time that a patient in Arm A of the primary trial lived with the disease without it getting worse was half a year. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00684983', 'Intervention': ['INTERVENTION 1: ', ' Arm A', ' Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Gi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 38f47a03-f71d-4072-a005-b954fb6069da | |
Single | Adverse Events | NCT00129376 | More than 2% of patients in the primary trial experienced a clinically significant inflammation of the back of the throat. | Contradiction | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT00129376', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin + Cyclophosphamide Followed Docetaxel', ' Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks late... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e41917b8-d921-4797-b845-0121a75104a4 | |
Single | Results | NCT02513472 | Cohort 1 patients in the primary trial surivied almost twice as long as those in cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT02513472', 'Intervention': ['INTERVENTION 1: ', ' Stratum 1: Eribulin Mesylate + Pembrolizumab', ' Participants with mTNBC who were never treated with systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrol... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bcb2d4a9-f2da-4a51-861b-3d5a9fbb6541 | |
Comparison | Adverse Events | NCT02491892 | NCT00887575 | Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial, this is due to the significant difference in cohort size. | Contradiction | [
0,
5,
6
] | [
0,
7,
8
] | {'Clinical Trial ID': 'NCT02491892', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab 420 mg', ' Participants received a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.', 'INTERVENTI... | {'Clinical Trial ID': 'NCT00887575', 'Intervention': ['INTERVENTION 1: ', ' Phase II- Sunitinib/Paclitaxel/Carboplatin', ' Systemic Therapy based on maximum tolerated dose (MTD) of the Phase I portion'], 'Eligibility': ['Inclusion Criteria:', ' Female patients, age 18 years', ' Histologically confirmed invasive ER-... | 3e56c28c-6d5c-49c4-aaf7-b4e2cb3ca2d7 |
Single | Results | NCT01881230 | The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01881230', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Nab-Paclitaxel + Gemcitabine', ' Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 27397dfc-b6cf-41a3-862c-a99ccd2ddd5d |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.